FDA Milestone: 75th Biosimilar Medication Is Approved!
U.S. Food and Drug Administration (FDA) shared on LinkedIn:
”Exciting Announcement!
The FDA has reached another milestone with the approval of its 75th biosimilar medication!
This achievement represents a major step forward in ensuring more patients have access to critical, life-saving treatments without compromising on quality or safety.
Learn more about biosimilars”
According to the FDA, a biosimilar is a biological product that closely resembles an already FDA-approved reference product and shows no clinically significant differences in safety or effectiveness.
Biosimilars are approved for use across a wide range of diseases, from Crohn’s disease to HER2-positive breast cancer.
For example, Zarxio can serve as an alternative to Neupogen (filgrastim), while the newly approved Avsola is intended to replace Remicade (infliximab) for various autoimmune conditions.
One key advantage of these drugs is that they maintain high standards of safety, efficacy, and quality, while also providing more cost-effective treatment options.
Thus, biosimilar products approved by FDA must also meet requirements mentioned in Biologics Price Competition and Innovation Act.
More on the latest FDA Approvals featured in Hemostasis Today.
-
Apr 12, 2026, 13:38Emmanuel J Favaloro: D-dimer testing in VTE diagnostic management studies
-
Apr 12, 2026, 13:26Flora Peyvandi: What Can Be Alternative to Warfarin
-
Apr 12, 2026, 13:21Can We Better Predict Who Is Most Likely to Have Another VTE After a First Event? – RPTH Journal
-
Apr 12, 2026, 13:18Gareth Owens: Advancing Aortic Disease Awareness Through Think Aorta
-
Apr 12, 2026, 13:11Denis Oduor: Apheresis Donation and Blood Component Therapy
-
Apr 12, 2026, 13:04Arsene Mekinian Featured in the Journal of Internal Medicine – Santé Arménie
-
Apr 12, 2026, 13:04Toward Nationwide Hemophilia Care in Armenia by 2030 – WFH
-
Apr 12, 2026, 12:56Chokri Ben Lamine: Clinical Dosing and Special Populations Guide for Apixaban
-
Apr 12, 2026, 12:04Riccardo Fumagalli: Long Term Complications Following Catheter Directed Thrombolysis in PE